By delivering mRNA into a cell, the cell could be induced to produce any protein encoded by the mRNA. The protein produced can be used for medical prevention or treatment. The translatability and stability of mRNA as well as its immunostimulatory activity are the key factors to be optimized for specific therapeutic application. mRNA holds the potential to revolutionize vaccination, protein replacement therapies, and the treatment of genetic diseases.
The global mRNA Therapy market is projected to reach US$ 84450 million in 2029, increasing from US$ 36520 million in 2022, with the CAGR of 13.2% during the period of 2023 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global mRNA Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Moderna
BioNTech
Pfizer
Arcturus Therapeutics Holdings Inc.
Astrazeneca
CureVac
Translate Bio
Regeneron Pharmaceuticals
Arcturus Therapeutics
Takeda Pharmaceutical Company
Novartis
Sanofi
Segment by Type
Vaccine
Drugs
Segment by Application
mRNA Targeted Delivery in vivo
Genetically Modified T cells
Transforming Nanoparticles to Develop Immunotherapy for Cancer
Small Molecule Drugs Discovery
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The mRNA Therapy report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global mRNA Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Vaccine
1.2.3 Drugs
1.3 Market by Application
1.3.1 Global mRNA Therapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 mRNA Targeted Delivery in vivo
1.3.3 Genetically Modified T cells
1.3.4 Transforming Nanoparticles to Develop Immunotherapy for Cancer
1.3.5 Small Molecule Drugs Discovery
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global mRNA Therapy Market Perspective (2018-2029)
2.2 mRNA Therapy Growth Trends by Region
2.2.1 Global mRNA Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 mRNA Therapy Historic Market Size by Region (2018-2023)
2.2.3 mRNA Therapy Forecasted Market Size by Region (2024-2029)
2.3 mRNA Therapy Market Dynamics
2.3.1 mRNA Therapy Industry Trends
2.3.2 mRNA Therapy Market Drivers
2.3.3 mRNA Therapy Market Challenges
2.3.4 mRNA Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top mRNA Therapy Players by Revenue
3.1.1 Global Top mRNA Therapy Players by Revenue (2018-2023)
3.1.2 Global mRNA Therapy Revenue Market Share by Players (2018-2023)
3.2 Global mRNA Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by mRNA Therapy Revenue
3.4 Global mRNA Therapy Market Concentration Ratio
3.4.1 Global mRNA Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by mRNA Therapy Revenue in 2022
3.5 mRNA Therapy Key Players Head office and Area Served
3.6 Key Players mRNA Therapy Product Solution and Service
3.7 Date of Enter into mRNA Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 mRNA Therapy Breakdown Data by Type
4.1 Global mRNA Therapy Historic Market Size by Type (2018-2023)
4.2 Global mRNA Therapy Forecasted Market Size by Type (2024-2029)
5 mRNA Therapy Breakdown Data by Application
5.1 Global mRNA Therapy Historic Market Size by Application (2018-2023)
5.2 Global mRNA Therapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America mRNA Therapy Market Size (2018-2029)
6.2 North America mRNA Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America mRNA Therapy Market Size by Country (2018-2023)
6.4 North America mRNA Therapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe mRNA Therapy Market Size (2018-2029)
7.2 Europe mRNA Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe mRNA Therapy Market Size by Country (2018-2023)
7.4 Europe mRNA Therapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific mRNA Therapy Market Size (2018-2029)
8.2 Asia-Pacific mRNA Therapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific mRNA Therapy Market Size by Region (2018-2023)
8.4 Asia-Pacific mRNA Therapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America mRNA Therapy Market Size (2018-2029)
9.2 Latin America mRNA Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America mRNA Therapy Market Size by Country (2018-2023)
9.4 Latin America mRNA Therapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa mRNA Therapy Market Size (2018-2029)
10.2 Middle East & Africa mRNA Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa mRNA Therapy Market Size by Country (2018-2023)
10.4 Middle East & Africa mRNA Therapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Moderna
11.1.1 Moderna Company Detail
11.1.2 Moderna Business Overview
11.1.3 Moderna mRNA Therapy Introduction
11.1.4 Moderna Revenue in mRNA Therapy Business (2018-2023)
11.1.5 Moderna Recent Development
11.2 BioNTech
11.2.1 BioNTech Company Detail
11.2.2 BioNTech Business Overview
11.2.3 BioNTech mRNA Therapy Introduction
11.2.4 BioNTech Revenue in mRNA Therapy Business (2018-2023)
11.2.5 BioNTech Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer mRNA Therapy Introduction
11.3.4 Pfizer Revenue in mRNA Therapy Business (2018-2023)
11.3.5 Pfizer Recent Development
11.4 Arcturus Therapeutics Holdings Inc.
11.4.1 Arcturus Therapeutics Holdings Inc. Company Detail
11.4.2 Arcturus Therapeutics Holdings Inc. Business Overview
11.4.3 Arcturus Therapeutics Holdings Inc. mRNA Therapy Introduction
11.4.4 Arcturus Therapeutics Holdings Inc. Revenue in mRNA Therapy Business (2018-2023)
11.4.5 Arcturus Therapeutics Holdings Inc. Recent Development
11.5 Astrazeneca
11.5.1 Astrazeneca Company Detail
11.5.2 Astrazeneca Business Overview
11.5.3 Astrazeneca mRNA Therapy Introduction
11.5.4 Astrazeneca Revenue in mRNA Therapy Business (2018-2023)
11.5.5 Astrazeneca Recent Development
11.6 CureVac
11.6.1 CureVac Company Detail
11.6.2 CureVac Business Overview
11.6.3 CureVac mRNA Therapy Introduction
11.6.4 CureVac Revenue in mRNA Therapy Business (2018-2023)
11.6.5 CureVac Recent Development
11.7 Translate Bio
11.7.1 Translate Bio Company Detail
11.7.2 Translate Bio Business Overview
11.7.3 Translate Bio mRNA Therapy Introduction
11.7.4 Translate Bio Revenue in mRNA Therapy Business (2018-2023)
11.7.5 Translate Bio Recent Development
11.8 Regeneron Pharmaceuticals
11.8.1 Regeneron Pharmaceuticals Company Detail
11.8.2 Regeneron Pharmaceuticals Business Overview
11.8.3 Regeneron Pharmaceuticals mRNA Therapy Introduction
11.8.4 Regeneron Pharmaceuticals Revenue in mRNA Therapy Business (2018-2023)
11.8.5 Regeneron Pharmaceuticals Recent Development
11.9 Arcturus Therapeutics
11.9.1 Arcturus Therapeutics Company Detail
11.9.2 Arcturus Therapeutics Business Overview
11.9.3 Arcturus Therapeutics mRNA Therapy Introduction
11.9.4 Arcturus Therapeutics Revenue in mRNA Therapy Business (2018-2023)
11.9.5 Arcturus Therapeutics Recent Development
11.10 Takeda Pharmaceutical Company
11.10.1 Takeda Pharmaceutical Company Company Detail
11.10.2 Takeda Pharmaceutical Company Business Overview
11.10.3 Takeda Pharmaceutical Company mRNA Therapy Introduction
11.10.4 Takeda Pharmaceutical Company Revenue in mRNA Therapy Business (2018-2023)
11.10.5 Takeda Pharmaceutical Company Recent Development
11.11 Novartis
11.11.1 Novartis Company Detail
11.11.2 Novartis Business Overview
11.11.3 Novartis mRNA Therapy Introduction
11.11.4 Novartis Revenue in mRNA Therapy Business (2018-2023)
11.11.5 Novartis Recent Development
11.12 Sanofi
11.12.1 Sanofi Company Detail
11.12.2 Sanofi Business Overview
11.12.3 Sanofi mRNA Therapy Introduction
11.12.4 Sanofi Revenue in mRNA Therapy Business (2018-2023)
11.12.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Moderna
BioNTech
Pfizer
Arcturus Therapeutics Holdings Inc.
Astrazeneca
CureVac
Translate Bio
Regeneron Pharmaceuticals
Arcturus Therapeutics
Takeda Pharmaceutical Company
Novartis
Sanofi
*If Applicable.